On October 23, 202, the 2025 Sichuan Large Enterprises & Major Groups Development Conference was held in Chengdu. During the conference, the Sichuan Provincial Enterprise Confederation and the Sichuan Provincial Entrepreneurs Association‌ jointly released the Sichuan Top 100 Enterprise Development Report (2025)and unveiled a series of rankings. Biokin Pharmaceutical was successfully selected for the "2025 Sichuan Top 100 Manufacturing Enterprises" list based on its comprehensive strength.

This Top 100 list not only comprehensively reflects the overall strength of Sichuan enterprises in terms of scale, efficiency, and innovation but also clearly demonstrates the development trends of Sichuan's industries in areas such as innovation and transformation, industrial chain collaboration, green and low-carbon development, and digital-intelligent integration. Across six advantageous industries—Electronic Information, Equipment Manufacturing, Food & Light Textiles, Energy & Chemicals, Advanced Materials, and Medical Health—as well as emerging fields like the Digital Economy, a cohort of Sichuan enterprises with core competitiveness is rapidly emerging.

As a high-tech enterprise focused on biopharmaceutical R&D and manufacturing, Biokin Pharmaceutical has consistently dedicated efforts to cutting-edge fields like macromolecular tumor therapy in recent years. Through independent R&D, it has advanced multiple innovative drugs into clinical stages, with gradual scale-up production planned for the future. This selection signifies high recognition of the company's technological prowess and market performance, and also reflects the positive achievements of Sichuan's manufacturing sector advancing towards higher-end, intelligent production.

Looking ahead, Biokin Pharmaceutical will leverage Sichuan's robust industrial ecosystem advantages to further increase R&D investment, accelerate the commercialization of innovative achievements, and contribute to Sichuan's goal of building a world-class biopharmaceutical industrial cluster.